8-K: CONMED Corporation Reports Solid First Quarter 2024 Results, Adjusts Full-Year Outlook

CONMED Corporation announced a 5.7% year-over-year increase in sales for the first quarter of 2024, alongside an adjusted earnings per share increase of 19.7%, while also adjusting its full-year revenue and earnings guidance due to currency headwinds.

Summary

• CONMED Corporation reported a 5.7% increase in sales to $312.3 million for the first quarter of 2024, compared to $295.5 million in the same period last year.
• Domestic revenue saw a 7.2% increase, while international revenue grew by 3.8% as reported and 4.2% in constant currency.
• Diluted net earnings per share (GAAP) were $0.63, a significant increase from $0.06 in the first quarter of 2023.
• Adjusted diluted net earnings per share were $0.79, a 19.7% increase compared to the first quarter of 2023.
• The company has revised its full-year revenue guidance to between $1.330 billion and $1.355 billion, down from the previous range of $1.340 billion to $1.365 billion, due to expected currency headwinds of approximately $10 million.
• Full-year adjusted diluted net earnings per share are now expected to be in the range of $4.25 to $4.35, compared to the prior range of $4.30 to $4.40, also due to currency headwinds.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong earnings growth and solid sales figures, but tempered by the lowered full-year guidance due to currency headwinds. The company is performing well, but faces external challenges.

Positives

• The company experienced solid growth in both sales and adjusted earnings per share.
• There was a significant increase in GAAP diluted net earnings per share from $0.06 to $0.63 year-over-year.
• Adjusted diluted net earnings per share increased by 19.7% compared to the same quarter last year.
• The company's gross profit margin improved from 52.6% to 55.1% year-over-year.
• Income from operations increased significantly from $12.7 million to $35.0 million year-over-year.

Negatives

• The company has lowered its full-year revenue guidance due to expected currency headwinds.
• The full-year adjusted diluted net earnings per share guidance has also been lowered due to currency headwinds.
• International revenue growth was lower than domestic revenue growth.

Risks

• The company faces risks related to foreign currency exchange rate fluctuations, which are expected to negatively impact revenue by approximately $10 million.
• The company's forward-looking statements are subject to various risks and uncertainties, as detailed in their annual report.
• The company's actual results may differ materially from the forward-looking statements due to various factors.

Future Outlook

The company has adjusted its full-year revenue and adjusted diluted net earnings per share guidance due to expected currency headwinds. Full-year revenue is now expected to be between $1.330 billion and $1.355 billion, and adjusted diluted net earnings per share are expected to be between $4.25 and $4.35.

Management Comments

• Curt R. Hartman, CONMED's Chair of the Board, President, and Chief Executive Officer, stated that 2024 is off to a solid start with the quarter delivering expected topand bottom-line growth and margin expansion.
• Management believes the company is well-positioned with a compelling and diverse portfolio to drive continued growth across the markets it serves.

Industry Context

CONMED operates in the medical technology industry, providing devices and equipment for surgical procedures. The company's performance is influenced by factors such as healthcare spending, technological advancements, and competition within the medical device market. The results indicate a solid start to the year, but the currency headwinds highlight the challenges of operating in a global market.

Comparison to Industry Standards

• CONMED's 5.7% revenue growth is a solid result in the medical device industry, but it is important to compare this to peers such as Stryker (SYK), Medtronic (MDT), and Johnson & Johnson (JNJ) to assess its relative performance.
• Stryker, for example, reported a 10.1% constant currency sales growth in their most recent quarter, indicating that CONMED's growth is below some of the industry leaders.
• Medtronic's recent results showed a 1.4% organic revenue growth, suggesting that CONMED is performing better than some of its larger competitors in terms of growth.
• The adjusted EPS growth of 19.7% is strong, but it is important to compare this to the adjusted EPS growth of other medical device companies to determine if it is above or below the industry average.
• CONMED's adjusted EBITDA margin of 18.0% is a key metric to compare against industry benchmarks, as companies like Intuitive Surgical (ISRG) often have higher margins due to their technology focus.

Stakeholder Impact

• Shareholders may react positively to the strong first quarter results, but negatively to the lowered full-year guidance.
• Employees may be impacted by the company's performance and future outlook.
• Customers will continue to rely on CONMED's products and services.
• Suppliers will be impacted by the company's sales and production volumes.

Next Steps

• The company will host a conference call to discuss the first quarter results.
• The company will continue to monitor and manage the impact of foreign currency exchange rates.
• The company will focus on driving growth across its diverse portfolio.

Key Dates

Keywords

financial results, earnings, revenue, medical devices, CONMED, sales growth, adjusted EPS, currency headwinds, surgical procedures, medical technology